CA2386740A1 - Combination treatment for alcoholism and alcohol dependence - Google Patents

Combination treatment for alcoholism and alcohol dependence Download PDF

Info

Publication number
CA2386740A1
CA2386740A1 CA002386740A CA2386740A CA2386740A1 CA 2386740 A1 CA2386740 A1 CA 2386740A1 CA 002386740 A CA002386740 A CA 002386740A CA 2386740 A CA2386740 A CA 2386740A CA 2386740 A1 CA2386740 A1 CA 2386740A1
Authority
CA
Canada
Prior art keywords
dichlorophenoxy
methylamine
alkyl
independently
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002386740A
Other languages
English (en)
French (fr)
Inventor
Harry Ralph Howard Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CA2386740A1 publication Critical patent/CA2386740A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002386740A 2001-05-23 2002-05-17 Combination treatment for alcoholism and alcohol dependence Abandoned CA2386740A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29308801P 2001-05-23 2001-05-23
US60/293,088 2001-05-23

Publications (1)

Publication Number Publication Date
CA2386740A1 true CA2386740A1 (en) 2002-11-23

Family

ID=23127615

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002386740A Abandoned CA2386740A1 (en) 2001-05-23 2002-05-17 Combination treatment for alcoholism and alcohol dependence

Country Status (11)

Country Link
US (2) US20030130322A1 (enExample)
EP (1) EP1262196A3 (enExample)
JP (1) JP2002370975A (enExample)
KR (1) KR20020090153A (enExample)
CN (1) CN1386503A (enExample)
AU (1) AU4068602A (enExample)
CA (1) CA2386740A1 (enExample)
HU (1) HUP0201722A2 (enExample)
NZ (1) NZ519032A (enExample)
PL (1) PL354110A1 (enExample)
ZA (1) ZA200204019B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2350327C2 (ru) * 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
US8758443B2 (en) 2005-05-06 2014-06-24 Titan Spine, Llc Implants with integration surfaces having regular repeating surface patterns
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
TW200803901A (en) * 2005-11-28 2008-01-16 Orexigen Therapeutics Inc Methods of treating anxiety disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
TW201811315A (zh) 2006-11-09 2018-04-01 美商歐瑞根治療有限公司 層狀醫藥調配物
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
MX2009006672A (es) * 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
NZ588037A (en) 2008-02-28 2012-08-31 Univ Virginia Patent Found Serotonin transporter gene SLC6A4 and treatment of alcoholism
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
SI2801625T1 (en) 2010-07-02 2018-04-30 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug addiction
US20130096173A1 (en) 2011-09-09 2013-04-18 Bankole A. Johnson Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
PT3730132T (pt) 2012-06-06 2022-08-16 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
CN114588467B (zh) * 2022-04-01 2022-11-29 广州蓝仕威克医疗科技有限公司 一种基于气体混合比例供气解决酒精中毒的方法及呼吸机
CN115671107B (zh) * 2022-12-29 2023-04-04 文韬创新药物研究(北京)有限责任公司 用于解酒的复方药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923283B (en) * 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
DK0782445T3 (da) * 1994-09-19 2002-05-06 Bristol Myers Squibb Pharma Co Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
HUP0105488A3 (en) * 1999-02-23 2005-07-28 Pfizer Prod Inc Monoamine reuptake inhibitors for treatment of cns disorders and pharmaceutical compositions containing the compounds
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
WO2001027068A1 (en) * 1999-10-13 2001-04-19 Pfizer Products Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors

Also Published As

Publication number Publication date
ZA200204019B (en) 2003-11-21
CN1386503A (zh) 2002-12-25
JP2002370975A (ja) 2002-12-24
US20040162316A1 (en) 2004-08-19
HUP0201722A2 (hu) 2003-07-28
EP1262196A2 (en) 2002-12-04
NZ519032A (en) 2003-10-31
EP1262196A3 (en) 2002-12-18
HU0201722D0 (enExample) 2002-07-29
AU4068602A (en) 2002-12-05
PL354110A1 (en) 2002-12-02
US20030130322A1 (en) 2003-07-10
KR20020090153A (ko) 2002-11-30

Similar Documents

Publication Publication Date Title
US20040162316A1 (en) Combination treatment for alcoholism and alcohol dependence
US6436938B1 (en) Combination treatment for depression
CA2344090C (en) Compositions and methods for treating female sexual dysfunction
TW524692B (en) 5HT1 receptor agonists and metoclopramide for the treatment of migraine
EP1238676B1 (en) Combination of a serotonin reuptake inhibitor and an atypical antipsychotic for use in depression, obsessive compulsive disorder and psychosis
US6365598B1 (en) Pyrroloquinolines for treatment of obesity
TWI226829B (en) Pharmaceutical compositions for treatment of partial responders or refractory depression
CA2398766A1 (en) Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction
HRP20020324A2 (en) Biaryl ether derivatives useful as monoamine reuptake inhibitors
CA2554617A1 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
EP1230921A1 (en) Combination treatment for depression
EP2029139B1 (en) Use of a p38 kinase inhibitor for treating psychiatric disorders
JPH02138214A (ja) 不安を治療する方法
WO2008075162A2 (en) Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction
JP2020508301A (ja) 7員アザ複素環を含有するデルタ−オピオイド受容体調節化合物、その使用方法及び製造方法
EP1260221A2 (en) Combination treatment for depression and anxiety
TW589181B (en) Lymphocytic activation inhibitor and remedial agent for autoimmune disease
CN114144179A (zh) 含血清素的试剂和5-ht1a受体拮抗剂
JPH10298078A (ja) 抗不安薬
CA2427098A1 (en) 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence
HK40065810A (zh) 含血清素的试剂和5-ht1a受体拮抗剂
HK1050479A (en) Combination treatment for alcoholism and alcohol dependence
MXPA00011353A (es) Uso de olanzapida en combinación con fluoxetina para terapia de la depresión refractaria
MXPA06008113A (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued